Closure of the left atrial appendage in patients with atrial fibrillation and risk for stroke is a increasing technology leading to exclusion of the left atrial appendage volume from the blood circulation and therefore protects from cardioembolic strokes- It is unclear if the volume reduction of the left atrium leads to a change in exercise capacity or Quality of life.
The monocentric trial deals with the endocrinological changes as a result of closure of the left atrial appendage with a internal closure device. Specially, the changes in atrial natriuretic peptide, brain natriuretic peptide and their impact on exercise capacity is on focus of the trial. The trial is planned as a all comers trial.
Study Type
OBSERVATIONAL
Enrollment
40
University of Jena
Jena, Germany
exercise capacity measured by maximal oxygen consumption
Change from baseline spiroergometry to 45 days to 6 months
Time frame: Baselina, 45 days, 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.